Since no single animal model of NASH is fully predictive of drug efficacy in humans, we explored FASN inhibition in three separate mouse diet-induced models spanning the spectrum of disease severity; a prevention model, a therapeutic model, and a therapeutic model with advanced fibrosis and tumor formation (FAT-NASH). This evidence concerns the gene FASN and metabolic dysfunction-associated steatohepatitis.